NCT06118138 is a clinical trial of Hyperbaric oxygen therapy (HBOT) in Post-COVID ME/CFS, sponsored by Charite University, Berlin, Germany.

Who is sponsoring NCT06118138?

NCT06118138 is sponsored by Charite University, Berlin, Germany.

What drugs are being tested in NCT06118138?

Interventions in NCT06118138: Hyperbaric oxygen therapy (HBOT).

What condition does NCT06118138 study?

NCT06118138 studies Post-COVID ME/CFS.

Is NCT06118138 still recruiting?

NCT06118138 is currently completed. Last updated 15 April 2026.

Last reviewed 2026-04-15 · How we verify

NCT06118138

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hyperbaric High Pressure Oxygen Therapy in Post-COVID Syndrome and ME/CFS

Completed Last updated 15 April 2026

What this trial tests

trial testing Hyperbaric oxygen therapy (HBOT) in Post-COVID ME/CFS in 60 participants. Completed in 31 December 2025.

Timeline

15 July 2023

Primary endpoint
31 December 2025

31 December 2025

Quick facts

Lead sponsor	Charite University, Berlin, Germany
Status	Completed
Study type	OBSERVATIONAL
Enrollment	60
Start date	15 July 2023
Primary completion	31 December 2025
Estimated completion	31 December 2025
Sites	1 location across Germany

Drugs / interventions tested

Hyperbaric oxygen therapy (HBOT)

Conditions studied

Post-COVID ME/CFS — all drugs for Post-COVID ME/CFS →

Sponsor

Charite University, Berlin, Germany

Who can join

Adults 18 to 65, any sex, with Post-COVID ME/CFS. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this observational study is to document symptom progression in 60 patients with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) who undergo Hyperbaric Oxygen Therapy (HBOT) following COVID or other infections. Participants will receive HBOT treatment as an additional option after completing the Chronic Fatigue Syndrome CARE (CFS\_CARE) study and will be invited to take part in this observational study. Patients will complete health evaluations in the form of questionnaires, including the 36-Item Short Form Health Survey (SF-36), to assess changes in ME/CFS-related symptoms after HBOT. Rather than evaluating the efficacy of HBOT itself, the study will focus on observing and documenting these changes. Its goal is to offer valuable insights into symptom progression in ME/CFS patients receiving HBOT, which can serve as a foundation for future interventional randomized controlled trials.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Hyperbaric oxygen therapy improves clinical symptoms and functional capacity and modulates thalamic connectivity in ME/CFS: a prospective cohort study.
Kim L, Cammà G, Peters CK, Mantwill M, et al · · 2026 · PMID 42249466 · DOI 10.1186/s12967-026-08324-6

Verify or expand the search:

Other Charite University, Berlin, Germany trials

Trials by the same sponsor.

NCT07486167 — Influence of Lung Volume Optimization Maneuver on Cardiac Output and Lung Compliance in Ventilated Children With Congeni · Phase 1, PHASE2 · not yet recruiting
NCT07476729 — International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020) · Phase 3 · not yet recruiting
NCT07503054 — Ovarian Cancer Screening and AI · NA · not yet recruiting
NCT07529197 — Observational Study on Immunoadsorption (IA) in Patients With Autoantibody-Positive Post-Infectious ME/CFS · recruiting
NCT07388693 — Feasibility of Integrating Olfactory Stimuli Into Virtual Reality Cue Exposure for Patients With Alcohol Dependence · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06118138 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Charite University, Berlin, Germany
Last refreshed: 15 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06118138.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing